# Chengdu Suncadia Medicine Co., Ltd. trials: 24 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials with Chengdu Suncadia Medicine Co., Ltd. as lead sponsor, 7 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Chengdu Suncadia Medicine Co., Ltd.: 24 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/chengdu-suncadia-medicine-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 7
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07940439 | A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-9308 Tablet as Monotherapy or Combination Therapy in... | Chengdu Suncadia Medicine Co., Ltd. | Phase 1/2 | Not yet recruiting | Solid Tumor | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940439) |
| November 16, 2026 | NCT07940166 | A Study of HRS-8046 in Patients With Advanced Solid Tumors: Safety, Tolerability, and Pharmacokinetics | Chengdu Suncadia Medicine Co., Ltd. | Phase 1 | Not yet recruiting | Solid Tumor | 175 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940166) |
| September 28, 2026 | NCT07844356 | The Safety and Efficacy of HR19034 in Children With Myopia | Chengdu Suncadia Medicine Co., Ltd. | Phase 2/3 | Completed | Slowing the Progression of Myopia in Children | 509 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07844356) |
| July 13, 2026 | NCT07698756 | A Clinical Study of HRS-8797 in Healthy Participants | Chengdu Suncadia Medicine Co., Ltd. | Phase 1 | Not yet recruiting | Atopic Dermatitis | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07698756) |
| May 29, 2026 | NCT07613866 | A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria | Chengdu Suncadia Medicine Co., Ltd. | Phase 2 | Not yet recruiting | Chronic Spontaneous Urticaria | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07613866) |
| May 13, 2026 | NCT07583212 | Phase I Study of HRS-1635 in B-cell Malignancies | Chengdu Suncadia Medicine Co., Ltd. | Phase 1 | Recruiting | B-cell Malignancy | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583212) |
| May 12, 2026 | NCT07582133 | A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy | Chengdu Suncadia Medicine Co., Ltd. | Phase 2 | Recruiting | Primary IgA Nephropathy | 380 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07582133) |
| April 24, 2026 | NCT07551167 | A Clinical Study of HRS-5765 in Healthy Participants | Chengdu Suncadia Medicine Co., Ltd. | Phase 1 | Recruiting | Heart Failure | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551167) |
| November 17, 2025 | NCT07230418 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Doses of HRS-3095... | Chengdu Suncadia Medicine Co., Ltd. | Phase 1 | Completed | Chronic Spontaneous Urticaria | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07230418) |
| June 27, 2025 | NCT07040787 | Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects | Chengdu Suncadia Medicine Co., Ltd. | Phase 1 | Completed | Complement Mediated Glomerular Diseases, Hemolytic Anemia | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07040787) |
| June 25, 2025 | NCT07035665 | A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects | Chengdu Suncadia Medicine Co., Ltd. | Phase 1 | Completed | IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07035665) |
| June 11, 2025 | NCT07014826 | A Trial of HRS-5965 Capsule in Primary IgA Nephropathy | Chengdu Suncadia Medicine Co., Ltd. | Phase 3 | Active not recruiting | Primary IgA Nephropathy | 389 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07014826) |
| December 4, 2024 | NCT06715943 | Efficacy and Safety of HRS-5965 in Patients With PNH Who Are Still Anemia After Anti-C5 Antibody Treatment | Chengdu Suncadia Medicine Co., Ltd. | Phase 3 | Completed | Paroxysmal Nocturnal Hemoglobinuria | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06715943) |
| November 12, 2024 | NCT06684041 | A Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Study, and QT Interval Study of HRS-5965 Capsules in Healthy Subjects | Chengdu Suncadia Medicine Co., Ltd. | Phase 1 | Completed | Hemolytic Anemia | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06684041) |
| November 5, 2024 | NCT06674915 | Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic Impairment | Chengdu Suncadia Medicine Co., Ltd. | Phase 1 | Completed | Complement Mediated Primary or Secondary Glomerular Diseases | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06674915) |
| September 19, 2024 | NCT06593938 | A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to... | Chengdu Suncadia Medicine Co., Ltd. | Phase 3 | Completed | Paroxysmal Nocturnal Hemoglobinuria | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06593938) |
| August 22, 2024 | NCT06567392 | A Study to Evaluate the Mass Balance of \[14C\] HRS-5965 in Healthy Adult Male Volunteers | Chengdu Suncadia Medicine Co., Ltd. | Phase 1 | Completed | Complement Mediated Primary or Secondary Glomerular Diseases | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06567392) |
| July 8, 2024 | NCT06490991 | Comparison of HRS-5965 Capsules and Tablets in Healthy Subjects | Chengdu Suncadia Medicine Co., Ltd. | Phase 1 | Completed | Paroxysmal Nocturnal Hemoglobinuria，IgA Nephropathy | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06490991) |
| February 2, 2024 | NCT06238544 | Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria | Chengdu Suncadia Medicine Co., Ltd. | Phase 2 | Active not recruiting | Paroxysmal Nocturnal Hemoglobinuria | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06238544) |
| November 18, 2023 | NCT06137768 | A Trial of HRS-5965 Tablets in Primary IgA Nephropathy | Chengdu Suncadia Medicine Co., Ltd. | Phase 2 | Completed | Primary IgA Nephropathy | 123 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06137768) |
| September 22, 2023 | NCT06051357 | Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria | Chengdu Suncadia Medicine Co., Ltd. | Phase 2 | Completed | Paroxysmal Nocturnal Hemoglobinuria | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06051357) |
| June 15, 2023 | NCT05905458 | A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on... | Chengdu Suncadia Medicine Co., Ltd. | Phase 2 | Completed | Chronic Hepatitis B | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05905458) |
| August 18, 2022 | NCT05505955 | Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency | Chengdu Suncadia Medicine Co., Ltd. | Phase 1 | Completed | Glomerulonephritis | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05505955) |
| August 6, 2021 | NCT04994080 | A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism | Chengdu Suncadia Medicine Co., Ltd. | Phase 3 | Unknown | Secondary Hyperparathyroidism | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04994080) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 12 |
| Phase 1/2 | 1 |
| Phase 2 | 6 |
| Phase 2/3 | 1 |
| Phase 3 | 4 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 14 |
| Not yet recruiting | 4 |
| Recruiting | 3 |
| Active not recruiting | 2 |
| Unknown | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hemoglobinuria, Paroxysmal | 5 |
| Glomerulonephritis, IGA | 4 |
| Anemia, Hemolytic | 2 |
| Chronic Urticaria | 2 |
| Hyperparathyroidism, Secondary | 1 |
| Glomerulonephritis | 1 |
| Heart Failure | 1 |
| Dermatitis, Atopic | 1 |
| Hepatitis B, Chronic | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [High schools in the United States](https://specstream.ai/data/businesses/high-schools/united-states)
- [Life insurance agencies in the United States](https://specstream.ai/data/businesses/life-insurance-agencies/united-states)
- [Packing services in the United States](https://specstream.ai/data/businesses/packing-services/united-states)
- [Real estate law firms in the United States](https://specstream.ai/data/businesses/real-estate-law-firms/united-states)
- [Tea wholesalers in the United States](https://specstream.ai/data/businesses/tea-wholesalers/united-states)
- [Workers compensation law firms in the United States](https://specstream.ai/data/businesses/workers-compensation-law-firms/united-states)
